Nektar Therapeutics
Negative sentiment towards NKTR reflected by a jump of 38.04% in short interest
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or ...
Keeping an Eye on Nektar Therapeutics (NKTR) After Insider Trading Activity
Nektar Therapeutics’s recently made public that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $62802.0 on Nov ...
Analyzing Nektar Therapeutics (NKTR) After Recent Trading Activity
Nektar Therapeutics’s recent filing unveils that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $62802.0 on Nov ...
Citigroup initates Nektar Therapeutics (NKTR) rating to a Buy
In a filing, Nektar Therapeutics revealed its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $62802.0 on Nov ...
Nektar Therapeutics [NKTR] Insider Activity: An Update for Investors
In a filing, Nektar Therapeutics revealed its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $62802.0 on Nov ...
Nektar Therapeutics’s latest rating changes from various analysts
Nektar Therapeutics’s filing revealed that its Chief R&D Officer Zalevsky Jonathan unloaded Company’s shares for reported $62802.0 on Nov 25 ...
